Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: Additional results

Digestive Diseases and Sciences

Volumn 55, Issue 2, 2010, Pages 338-345

  Cutler, Alan ^a   Robinson, Malcolm ^b   Murthy, Anita ^c   Delemos, Byron ^d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c EISAI INC   (United States)

^d Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Gastroesophageal reflux disease; Heartburn; Rabeprazole; Regurgitation

Indexed keywords

ANTACID AGENT; CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ENZYME INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ERUCTATION; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; UNITED STATES;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSCOPY, GASTROINTESTINAL; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; FEMALE; FOLLOW-UP STUDIES; HEARTBURN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROTON-TRANSLOCATING ATPASES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 76849091867     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0864-7     Document Type: Article

References (24)

1. JF Johanson 2000 Epidemiology of esophageal and supraesophageal reflux injuries Am J Med 108 Suppl 4a 99S 103S 10.1016/S0002-9343(99)00347-2 10.1016/S0002-9343(99)00347-2 10718460 (Pubitemid 30133432)
2. GR Locke III NJ Talley SL Fett AR Zinsmeister LJ Melton III 1997 Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota Gastroenterology 112 5 1448 1456 10.1016/S0016-5085(97)70025-8 10.1016/S0016-5085(97)70025-8 9136821
3. MA Eloubeidi D Provenzale 2000 Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus Am J Gastroenterol 95 8 1881 1887 10.1111/j.1572-0241.2000.02235.x 10.1111/j.1572-0241.2000.02235.x 1:STN:280:DC%2BD3cvhs1aksg%3D%3D 10950030
4. EC Klinkenberg-Knol HP Festen SG Meuwissen 1995 Pharmacological management of gastro-oesophageal reflux disease Drugs 49 5 695 710 10.2165/00003495-199549050-00005 10.2165/00003495-199549050-00005 1:STN:280:DyaK2MzisVChsw%3D%3D 7601011
5. CA Flynn 2001 The evaluation and treatment of adults with gastroesophageal reflux disease J Fam Pract 50 1 61 63
6. R Fass MB Fennerty N Vakil 2001 Nonerosive reflux disease-current concepts and dilemmas Am J Gastroenterol 96 2 303 314 1:STN:280: DC%2BD3M7ot12itQ%3D%3D 11232668
7. N Chiba 2004 Treat the patients' main dyspepsia complaint, not the ROME criteria Am J Gastroenterol 99 6 1059 1062 10.1111/j.1572-0241.2004.30488.x 10.1111/j.1572-0241.2004.30488.x 15180725 (Pubitemid 38917808)
8. N Chiba CJ De Gara JM Wilkinson RH Hunt 1997 Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis Gastroenterology 112 6 1798 1810 10.1053/gast.1997.v112.pm9178669 10.1053/gast.1997.v112.pm9178669 1:STN:280:DyaK2szit1Sitw%3D%3D 9178669 (Pubitemid 27240763)
9. D Pantoflickova G Dorta M Ravic P Jornod AL Blum 2003 Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors Aliment Pharmacol Ther 17 12 1507 1514 10.1046/j.1365-2036.2003.01496.x 10.1046/j.1365-2036.2003.01496.x 1:CAS:528:DC%2BD3sXmt1Ogur8%3D 12823153 (Pubitemid 36831441)
10. MP Williams J Sercombe MI Hamilton RE Pounder 1998 A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects Aliment Pharmacol Ther 12 11 1079 1089 10.1046/j.1365-2036.1998.00418.x 10.1046/j.1365-2036.1998.00418.x 1:CAS:528:DyaK1cXotVerurs%3D 9845397 (Pubitemid 28508721)
11. CP Dekkers JA Beker B Thjodleifsson A Gabryelewicz NE Bell TJ Humphries 1999 Double-blind comparison [correction of double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European rabeprazole study group Aliment Pharmacol Ther 13 1 49 57 10.1046/j.1365-2036. 1999.00438.x 10.1046/j.1365-2036.1999.00438.x 1:CAS:528:DyaK1MXhsV2mtLc%3D 9892879 (Pubitemid 29048056)
12. JC Delchier G Cohen TJ Humphries 2000 Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease Scand J Gastroenterol 35 12 1245 1250 10.1080/003655200453566 10.1080/003655200453566 1:CAS:528: DC%2BD3MXot1Gisw%3D%3D 11199361 (Pubitemid 32051636)
13. B Thjodleifsson JA Beker C Dekkers T Bjaaland V Finnegan TJ Humphries 2000 Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European rabeprazole study group Dig Dis Sci 45 5 845 853 10.1023/A:1005548318996 10.1023/A:1005548318996 1:CAS:528:DC%2BD3cXjt1Cqt74%3D 10795744 (Pubitemid 30238242)
14. A Caos J Breiter C Perdomo J Barth 2005 Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States Aliment Pharmacol Ther 22 3 193 202 10.1111/j.1365-2036.2005.02555.x 10.1111/j.1365-2036.2005.02555.x 1:CAS:528:DC%2BD2MXhtVagsrfF 16091056 (Pubitemid 41153061)
15. Jacobson BC, DeLemos B, Sun Y, Xiang J, LoCocos J, Li H, et al. PPI efficacy in overweight/obese patients with erosive GERD: rabeprazole (RAB) 20 mg vs. omeprazole (OME) 20 mg. 2007 [abstract, submitted to American College of Gastroenterology; Philadelphia October 12-17].
16. T Ishizaki Y Horai 1999 Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole Aliment Pharmacol Ther 13 Suppl 3 27 36 10.1046/j.1365-2036.1999.00022.x 10.1046/j.1365-2036.1999. 00022.x 1:CAS:528:DyaK1MXlvVGhurk%3D 10491726
17. M Robinson S Fitzgerald R Hegedus A Murthy L Jokubaitis 2002 Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis Aliment Pharmacol Ther 16 3 445 454 10.1046/j.1365-2036.2002.01181.x 10.1046/j.1365-2036.2002.01181.x 1:CAS:528:DC%2BD38XivV2ltLY%3D 11876697 (Pubitemid 34214523)
18. G Holtmann P Bytzer M Metz V Loeffler AL Blum 2002 A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease Aliment Pharmacol Ther 16 3 479 485 10.1046/j.1365-2036.2002.01207.x 10.1046/j.1365-2036.2002.01207.x 1:CAS:528:DC%2BD38XivV2ltb8%3D 11876701 (Pubitemid 34214527)
19. P Miner Jr W Orr J Filippone L Jokubaitis S Sloan 2002 Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial Am J Gastroenterol 97 6 1332 1339 10.1111/j.1572-0241.2002.05769.x 10.1111/j.1572-0241.2002.05769.x 1:CAS:528:DC%2BD2MXjtFGnsLs%3D 12094846 (Pubitemid 34664773)
20. PJ Kahrilas P Miner J Johanson L Mao L Jokubaitis S Sloan 2005 Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease Dig Dis Sci 50 11 2009 2018 10.1007/s10620-005-3000-3 10.1007/s10620-005-3000-3 1:CAS:528:DC%2BD2MXhtFemtb3N 16240208 (Pubitemid 41504082)
21. PE Patterson SM Harding 1999 Gastroesophageal reflux disorders and asthma Curr Opin Pulm Med 5 1 63 67 10.1097/00063198-199901000-00011 10.1097/00063198-199901000-00011 10813252
22. M Ruth I Mansson N Sandberg 1991 The prevalence of symptoms suggestive of esophageal disorders Scand J Gastroenterol 26 1 73 81 10.3109/00365529108996486 10.3109/00365529108996486 1:STN:280:DyaK3M7ntlansw%3D%3D 2006401
23. JF Johanson R Siddique AM Damiano L Jokubaitis A Murthy A Bhattacharjya 2002 Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease Dig Dis Sci 47 11 2574 2578 10.1023/A:1020532714664 10.1023/A:1020532714664 1:CAS:528:DC%2BD38XnvVSnsrw%3D 12452397 (Pubitemid 35305468)
24. A Damiano R Siddique X Xu J Johanson S Sloan 2003 Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole Dig Dis Sci 48 4 657 662 10.1023/A:1022812103923 10.1023/A:1022812103923 1:CAS:528: DC%2BD3sXitFegs7w%3D 12741452 (Pubitemid 36390664)